After withdrawal, GSK touts another Blenrep combo win as …
WEBMar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) is a new antibody-drug conjugate for relapsed/refractory multiple myeloma. It extended progression-free survival and had a positive overall survival trend compared to standard of care in two phase III trials.
ASCO 2024 – Blenrep “should return” to the US - ApexOnco
WEBJun 2, 2024 · After Blenrep’s surprise win in the Dreamm-7 and 8 studies the withdrawn GSK drug should return to the market, ASCO has heard. The view was expressed at a press briefing ahead of the full Dreamm-8 data being …
GSK backs up its Blenrep rehab bid with survival data
WEBFeb 7, 2024 · GSK has reported data it hopes will allow a return to the US for Blenrep, the first BCMA-targeting drug to launch for multiple myeloma.
GSK will pull Blenrep from US market after failed trial
WEBSep 2, 2024 · Blenrep, a BCMA-targeted ADC for multiple myeloma, failed to improve survival in a confirmatory study and will be pulled from the US market. GSK will continue other trials of Blenrep, including a...
GSK’s Quest to Bring Myeloma Drug Back to the Market ... - MedCity News
WEBJun 2, 2024 · Blenrep is an antibody drug conjugate (ADC) that targets the BCMA protein on multiple myeloma cells, delivering to them a payload of toxic chemotherapy.
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBGlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · The combination of Blenrep with Takeda’s Velcade and the steroid dexamethasone (Vd) significantly cut the risk of progression or death by 59% compared with Johnson & Johnson’s Darzalex and Vd in...
GSK provides an update on Blenrep (belantamab mafodotin …
WEBNov 22, 2022 · GSK announces the withdrawal of Blenrep, a treatment for relapsed or refractory multiple myeloma, from the US market following the FDA request based on the DREAMM-3 trial outcome. GSK continues to support patients and plans to pursue other clinical trials for Blenrep.
GSK to stop selling blood cancer drug Blenrep in United States
WEBNov 22, 2022 · GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business.